BREYANZI

🇺🇸 United States

FDA Page

Effective Date: Feb 20, 2026
Approval ID: 594bb413-af3b-4b97-afb3-bfe2b174f2ed
Products: 0 registered
Version: 15

Regulatory Information

Labeling Type

CELLULAR THERAPY

Status

Approved

Full Title

These highlights do not include all the information needed to use BREYANZI safely and effectively. See full prescribing information for BREYANZI. BREYANZI (lisocabtagene maraleucel) suspension for intravenous infusion Initial U.S. Approval: 2021

Quick Stats

Total Products0

Labelers0

Label Sections0

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.